Erratum: Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis (Diabetologia DOI: 10.1007/s00125-010-1702-3);Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

Diabetologia

Volumn 53, Issue 7, 2010, Pages 1258-1269

  Schernthaner, G ^p   Barnett, A H ^a   Betteridge, D J ^b   Carmena, R ^c   Ceriello, A ^d   Charbonnel, B ^e   Hanefeld, M ^f   Lehmann, R ^g   Malecki, M T ^h   Nesto, R ⁱ   Pirags, V ^j   Scheen, A ^k   Seufert, J ^l   Sjoholm A ^m   Tsatsoulis, A ⁿ   DeFronzo, R ^o  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY OF VALENCIA   (Spain)

^d UNIVERSITY OF UDINE   (Italy)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f Center for Clinical Studies   (Germany)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h JAGIELLONIAN UNIVERSITY   (Poland)

ⁱ LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^j UNIVERSITY OF LATVIA   (Latvia)

^k UNIVERSITY OF LIÈGE   (Belgium)

^l UNIVERSITY OF FREIBURG   (Germany)

^m KAROLINSKA INSTITUTE   (Sweden)

ⁿ UNIVERSITY OF IOANNINA   (Greece)

^o UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^p NONE

more..

Author keywords

ADA consensus statement; Algorithm; Cardiovascular risk; EASD consensus statement; Glucose lowering therapy; Hyperglycaemia; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; DIAMICRON MR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; ALGORITHM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSENSUS DEVELOPMENT; DIABETES CONTROL; DRUG HALF LIFE; EVIDENCE BASED MEDICINE; FLUID RETENTION; FRACTURE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS CANCER; PATIENT CARE; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; WEIGHT GAIN;

EID: 77955657408     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-010-1797-6     Document Type: Erratum

References (102)

1. Nathan DM, Buse JB, Davidson MB et al (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49:1711-1721.
2. Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17-30.
3. American Diabetes Association (2008) Clinical practice recommendations 2008. Diabetes Care 31:S1-S2.
4. Schünemann HJ, Fretheim A, Oxman AD, WHO Advisory Committee on Health Research (2006) Improving the use of research evidence in guideline development: 1. Guidelines for guidelines. Health Res Policy Syst 4:13.
5. Turner T, Misso M, Harris C, Green S (2008) Development of evidence-based clinical practice guidelines (CPGs): comparing approaches. Implement Sci 3:45.
6. Rosenbrand K, Van Croonenborg J, Wittenberg J (2008) Guideline development. Stud Health Technol Inform 139:3-21.
7. Atkins D, Best D, Briss PA et al (2004) Grading quality of evidence and strength of recommendations. BMJ 328:1490.
8. American Diabetes Association (ADA) (2009) Standards of medical care in diabetes-2009. Diabetes Care 32(Suppl 1): S13-S61.
9. DeFronzo RA (2009) From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773-795.
10. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P, behalf of the Quartet Study Group (2004) Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 89:6068-6076.
11. Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P, behalf of the QUARTET Study Group (2005) A longterm comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallelgroup comparison trial. Diabet Med 22:399-405.
12. Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443.
13. Bolen S, Wilson L, Vassy J et al (2007) Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147:386-399.
14. Amori RE, Lau J, Pittas AG (2007) Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298:194-206.
15. Madsbad S (2009) Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)-preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 23:463-477.
16. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C (2008) Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 4:753-768.
17. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP, Sitagliptin Study 024 Group (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, doubleblind, non-inferiority trial. Diabetes Obes Metab 9:194-205.
18. Ferrannini E, Fonseca V, Zinman B et al (2009) Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 11:157-166.
19. Horton ES (2009) Defining the role of basal and prandial insulin for optimal glycemic control. J Am Coll Cardiol 53(5 Suppl): S21-S27.
20. Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ (2009) Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 52:1990-2000.
21. Holman RR, Farmer AJ, Davies MJ, 4-T Study Group et al (2009) Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 361:1736-1747.
22. Monami M, Marchionni N, Mannucci E (2008) Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 81:184-189.
23. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T (2008) Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 371:1073-1084.
24. Kann PH, Wascher T, Zackova V et al (2006) Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 114:527-532.
25. Raskin P, Allen E, Hollander P et al (2005) Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28:260-265.
26. Robbins DC, Beisswenger PJ, Ceriello A et al (2007) Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther 29:2349-2364.
27. Ilag LL, Kerr L, Malone JK, Tan MH (2007) Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidencebased comparison. Clin Ther 29 (Spec No):1254-1270.
28. Hollander P, Cooper J, Bregnhøj J, Pedersen CB (2008) A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 30:1976-1987.
29. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G (2008) A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulinnaive people with type 2 diabetes. Diabetologia 51:408-416.
30. 1c, fasting and postprandial plasma glucose levels to glycaemic control in type 2 diabetes. Int J Clin Pract 62:1935-1942.
31. Matthaei S, Bierwirth R, Fritsche A et al (2009) Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes 117: 522-557.
32. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865.
33. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589.
34. Johnson JA, Majundar SR, Simpson SH, Toth EL (2002) Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25:2244-2248.
35. Evans JM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936.
36. Tzoulaki I, Molokhia M, Curcin V et al (2009) Risk of cardiovascular disease and all cuase mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339:b4731.
37. Meinert CL, Knatterud GL, Prout TE, Klimt CR (1970) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetesm. II. Mortality results. Diabetes 19(Suppl):789-830.
38. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853.
39. The ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572.
40. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr (1999) Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 33:119-124.
41. The University Group Diabetes Program (1975) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of phenformin therapy. Diabetes 24(Suppl 1):65-184.
42. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA (2008) Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies. Diabetes Care 31:1672-1678.
43. Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653.
44. Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986.
45. Ohkubo Y, Kishikawa H, Araki E et al (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117.
46. Muis MJ, Bots ML, Grobbee DE, Stolk RP (2005) Insulin treatment and cardiovascular disease; friend or foe? A point of view. Diabet Med 22:118-126.
47. Engel-Nitz NM, Martin S, Sun P, Buesching D, Fonseca V (2008) Cardiovascular events and insulin therapy: a retrospective cohort analysis. Diabetes Res Clin Pract 81:97-104.
48. Kumar R, Lee TT, Jeremias A et al (2007) Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients. Am J Cardiol 100:1187-1191.
49. Margolis DJ, Hoffstad O, Strom BL (2008) Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 17:753-759.
50. Anselmino M, Ohrvik J, Malmberg K, Standl E, Rydén L, Euro Heart Survey Investigators (2008) Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J 29:177-184.
51. Malmberg K, Norhammar A, Wedel H, Rydén L (1999) Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction. Long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study. Circulation 99:2626-2632.
52. Malmberg K, Rydén L, Wedel H et al (2005) Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 26:650-651.
53. Mellbin LG, Malmberg K, Norhammer A, Wedel H, Ryden L, for the DIGAMI 2 Investigators (2008) The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 29:166-176.
54. Raz I, Wilson PW, Strojek K et al (2009) Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 32:381-386.
55. Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitA-zone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279-1289.
56. Betteridge DJ, DeFronzo RA, Chilton RJ (2008) PROactive: time for a critical appraisal. Eur Heart J 29:969-983.
57. Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N (2008) Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 10:1221-1238.
58. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298:1180-1188.
59. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471.
60. Singh S, Loke YK, Furberg CD (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298:1189-1195.
61. Diamond GA, Bax L, Kaul S (2007) Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 147:578-581.
62. Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125-2135.
63. Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S (2007) A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 16: 1065-1071.
64. Walker AM, Koro CE, Landon J (2008) Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. Pharmacoepidemiol Drug Saf 17:760-768.
65. Hausenloy DJ, Yellon DM (2008) GLP-1 therapy: beyond glucose control. Circ Heart Fail 1:147-149.
66. Timmers L, Henriques JP, de Kleijn DP et al (2009) Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53:501-510.
67. Noyan-Ashraf MH, Momen MA, Ban K et al (2009) The GLP- 1R agonist liraglutide activates cytoprotective pathways and improves outcomes following experimental myocardial infarction in mice. Diabetes 58:975-983.
68. Wajchenberg BL (2007) Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 28:187-218.
69. The Dream (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 368:1096-1105.
70. Defronzo RA, Banerji M, Bray GA et al (2009) Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord 29:9-17.
71. Chen H-S, Wu T-E, Jap T-S, Hsiao L-C, Lee S-H, Lin H-D (2008) Beneficial effects of insulin on glycemic control and β-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 31:1927-1932.
72. Weng J, Li Y, Xu W et al (2008) Effect of intensive insulin therapy on β-cell function and glycemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371:1753-1760.
73. Klonoff DC, Buse JB, Nielsen LL et al (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24:275-286.
74. Bunck MC, Diamant M, Corner A et al (2009) One-year treatment with exenatide improves beta-cell function, compared to insulin glargine, in metformin treated type 2 diabetes patients: a randomized, controlled trial. Diabetes Care 32:762-768.
75. Rydén L, Standl E, Bartnik M et al (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28:88-136.
76. Buse JB, Tan MH, Prince MJ, Erickson PP (2004) The effects of oral anti-hyperglycemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 6:133-156.
77. Chiquette E, Ramirez G, DeFronzo R (2004) A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 164:2097-2104.
78. Betteridge DJ (2007) Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes Metab 9:640-647.
79. Mazzone T, Meyer PM, Feinstein SB et al (2006) Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296:2572-2581.
80. Nissen SE, Nicholls SJ, Wolski K et al (2008) Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299: 1561-1573.
81. Dandona P, Chaudhuri A, Ghanim H, Mohanty P (2008) Use of insulin to improve glycemic control in diabetes mellitus. Cardiovasc Drugs Ther 22:241-251.
82. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G (2006) Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 29:554-559.
83. Triplitt C, Glass L, Miyazaki Y et al (2006) Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea. Diabetes Care 29:2371-2377.
84. Matikainen N, Mänttäri S, Schweizer A et al (2006) Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49:2049-2057.
85. Schernthaner G (2009) Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. Int J Clin Pract 63:912-929.
86. Bailey CJ (2008) Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther 22:215-224.
87. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI, The Rosiglitazone Clinical Trials Study Group (2001) Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86:280-288.
88. Miyazaki Y, Mahankali A, Matsuda M et al (2002) Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87:2784-2791.
89. Hermann LS, Schersten B, Bitzen PO, Kjellström T, Lindgärde F, Melander A (1994) Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 17:1100-1109.
90. Erdmann E, Wilcox RG (2008) Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J 29:12-20.
91. Eurich DT, McAlister FA, Blackburn DF et al (2007) Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 335:497-501.
92. Bodmer M, Meier C, Kraenzlin ME, Meier CR (2009) Risk of fractures with glitazones: a critical review of the evidence to date. Drug Saf 32:539-547.
93. US Food and Drug Administration (2008) Exenatide (marketed as Byetta) information (18 August 2008 update). Available from www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm, accessed 16 January 2010.
94. U.S. Food and Drug Administration (2008) Sitagliptin (marketed as Januvia and Janumet) information (issued 25 September 2009). Available from www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm183768.htm, accessed 16 January 2010.
95. Bain SC, Stephens JW (2008) Exenatide and pancreatitis: an update. Expert Opin Drug Saf 7:643-644.
96. Dore DD, Seeger JD, Arnold Chan K (2009) Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 25:1019-1027.
97. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL (2009) Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137:482-488.
98. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620-1625.
99. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777.
100. The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559.
101. 1c in people with type 2 diabetes: a retrospective cohort study. Lancet 375:481-489.
102. Woo V (2009) Important differences: Canadian Diabetes Association 2008 clinical practice guidelines and the consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:552-553.